Committee Opinion No. 539: Adolescents and long-acting reversible contraception: Implants and intrauterine devices

Obstetrics and Gynecology

Volumn 120, Issue 4, 2012, Pages 983-988

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

COPPER INTRAUTERINE DEVICE; MEDROXYPROGESTERONE ACETATE;

ADOLESCENCE; BODY WEIGHT; CONDOM; CONFIDENTIALITY; DEVICE SAFETY; FEMALE INFERTILITY; HIGH RISK POPULATION; HUMAN; INFORMED CONSENT; INTRAUTERINE CONTRACEPTIVE DEVICE; MEDICAL FEE; NULLIPARA; PATIENT COUNSELING; PATIENT SATISFACTION; PREGNANCY RATE; PRIORITY JOURNAL; PUERPERIUM; REVIEW; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; VAGINA BLEEDING; VAGINA RING;

ADOLESCENT; ADOLESCENT BEHAVIOR; ADOLESCENT HEALTH SERVICES; CONFIDENTIALITY; CONTRACEPTIVE AGENTS, FEMALE; DESOGESTREL; DIRECTIVE COUNSELING; FEMALE; HUMANS; INFORMED CONSENT BY MINORS; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; PATIENT ACCEPTANCE OF HEALTH CARE; PREGNANCY; PREGNANCY IN ADOLESCENCE; SEXUAL BEHAVIOR; UNITED STATES;

EID: 84866928578     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e3182723b7d     Document Type: Review

References (54)

1. Abma JC, Martinez GM, Copen CE. Teenagers in the United States: sexual activity, contraceptive use, and childbearing, National Survey of Family Growth 2006-2008. National Center for Health Statistics. Vital Health Stat 23 2010;(30):1-79.
2. Finer LB, Zolna MR. Unintended pregnancy in the United States: incidence and disparities, 2006. Contraception 2011;84:478-85.
3. Finer LB, Jerman J, Kavanaugh MC. Changes in use of long-acting contraceptive methods in the United States, 2007-2009. Fertil Steril 2012; DOI: 10.1016/j.fertnstert. 2012.06.027.
4. Mosher WD, Jones J. Use of contraception in the United States: 1982-2008. Vital Health Stat 23 2010;(29):1-44.
5. Zibners A, Cromer BA, Hayes J. Comparison of continuation rates for hormonal contraception among adolescents. J Pediatr Adolesc Gynecol 1999;12:90-4.
6. Raine TR, Foster-Rosales A, Upadhyay UD, Boyer CB, Brown BA, Sokoloff A, et al. One-year contraceptive continuation and pregnancy in adolescent girls and women initiating hormonal contraceptives. Obstet Gynecol 2011; 117:363-71.
7. Peipert JF, Zhao Q, Allsworth JE, Petrosky E, Madden T, Eisenberg D, et al. Continuation and satisfaction of reversible contraception. Obstet Gynecol 2011;117:1105-13.
8. Winner B, Peipert JF, Zhao Q, Buckel C, Madden T, Allsworth JE, et al. Effectiveness of long-acting reversible contraception. N Engl J Med 2012;366:1998-2007.
9. Fleming KL, Sokoloff A, Raine TR. Attitudes and beliefs about the intrauterine device among teenagers and young women. Contraception 2010;82:178-82.
10. Spies EL, Askelson NM, Gelman E, Losch M. Young women's knowledge, attitudes, and behaviors related to longacting reversible contraceptives. Womens Health Issues 2010;20:394-9.
11. Harper CC, Blum M, de Bocanegra HT, Darney PD, Speidel JJ, Policar M, et al. Challenges in translating evidence to practice: the provision of intrauterine contraception. Obstet Gynecol 2008;111:1359-69.
12. Mestad R, Secura G, Allsworth JE, Madden T, Zhao Q, Peipert JF. Acceptance of long-acting reversible contraceptive methods by adolescent participants in the Contraceptive CHOICE Project. Contraception 2011;84:493-8.
13. Espey E, Ogburn T. Long-acting reversible contraceptives: intrauterine devices and the contraceptive implant. Obstet Gynecol 2011;117:705-19.
14. Steinbock B. Coercion and long-term contraceptives. Hastings Cent Rep 1995;25:S19-22.
15. Farley TM, Rosenberg MJ, Rowe PJ, Chen JH, Meirik O. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet 1992;339:785-8.
16. Grimes DA. Intrauterine device and upper-genital-tract infection. Lancet 2000;356:1013-9.
17. Mohllajee AP, Curtis KM, Peterson HB. Does insertion and use of an intrauterine device increase the risk of pelvic inflammatory disease among women with sexually transmitted infection? A systematic review. Contraception 2006;73:145-53.
18. Faundes A, Telles E, Cristofoletti ML, Faundes D, Castro S, Hardy E. The risk of inadvertent intrauterine device insertion in women carriers of endocervical Chlamydia trachomatis. Contraception 1998;58:105-9.
19. Skjeldestad FE, Halvorsen LE, Kahn H, Nordbo SA, Saake K. IUD users in Norway are at low risk for genital C. trachomatis infection. Contraception 1996;54:209-12.
20. Suhonen S, Haukkamaa M, Jakobsson T, Rauramo I. Clinical performance of a levonorgestrel-releasing intrauterine system and oral contraceptives in young nulliparous women: a comparative study. Contraception 2004;69:407-12.
21. Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception 1994; 49:56-72.
22. Toivonen J, Luukkainen T, Allonen H. Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years' comparative experience of levonorgestrel- and copper-releasing intrauterine devices. Obstet Gynecol 1991; 77:261-4.
23. Hubacher D, Lara-Ricalde R, Taylor DJ, Guerra-Infante F, Guzman-Rodriguez R. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. N Engl J Med 2001;345:561-7.
24. Hov GG, Skjeldestad FE, Hilstad T. Use of IUD and subsequent fertility-follow-up after participation in a randomized clinical trial. Contraception 2007;75:88-92.
25. Allen RH, Bartz D, Grimes DA, Hubacher D, O'Brien P. Interventions for pain with intrauterine device insertion. Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No.: CD007373. DOI: 10.1002/14651858.CD007373. pub2.
26. Edelman AB, Schaefer E, Olson A, Van Houten L, Bednarek P, Leclair C, et al. Effects of prophylactic misoprostol administration prior to intrauterine device insertion in nulliparous women. Contraception 2011;84:234-9.
27. Heikinheimo O, Inki P, Kunz M, Parmhed S, Anttila AM, Olsson SE, et al. Double-blind, randomized, placebocontrolled study on the effect of misoprostol on ease of consecutive insertion of the levonorgestrel-releasing intrauterine system. Contraception 2010;81:481-6.
28. Swenson C, Turok DK, Ward K, Jacobson JC, Dermish A. Self-administered misoprostol or placebo before intrauterine device insertion in nulliparous women: a randomized controlled trial. Obstet Gynecol 2012;120:341-7.
29. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2010. Atlanta (GA): CDC; 2011. Available at: http://www.cdc.gov/ std/stats10/surv2010.pdf. Retrieved June 29, 2012.
30. Workowski KA, Berman S. Sexually transmitted diseases treatment guidelines, 2010. Centers for Disease Control and Prevention (CDC) [published erratum appears in MMWR Morb Mortal Wkly Rep 2011;60:18]. MMWR Recomm Rep 2010(RR-12);59:1-110.
31. U S. Medical Eligibility Criteria for Contraceptive Use, 2010. Centers for Disease Control and Prevention (CDC). MMWR Recomm Rep 2010;59(RR-4):1-86.
32. Long-acting reversible contraception: implants and intrauterine devices. Practice Bulletin No. 121. American College of Obstetricians and Gynecologists. Obstet Gynecol 2011;118:184-96.
33. Grimes DA, Lopez LM, Schulz KF. Antibiotic prophylaxis for intrauterine contraceptive device insertion. Cochrane Database of Systematic Reviews 1999, Issue 3. Art. No.: CD001327. DOI: 10.1002/14651858.CD001327.
34. Deans EI, Grimes DA. Intrauterine devices for adolescents: a systematic review. Contraception 2009;79:418-23.
35. Lyus R, Lohr P, Prager S. Use of the Mirena LNG-IUS and Paragard CuT380A intrauterine devices in nulliparous women. Board of the Society of Family Planning. Contraception 2010;81:367-71.
36. Thonneau P, Almont T, de La Rochebrochard E, Maria B. Risk factors for IUD failure: results of a large multicentre case-control study. Hum Reprod 2006;21:2612-6.
37. Darney P, Patel A, Rosen K, Shapiro LS, Kaunitz AM. Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials. Fertil Steril 2009;91:1646-53.
38. Mansour D, Korver T, Marintcheva-Petrova M, Fraser IS. The effects of Implanon on menstrual bleeding patterns. Eur J Contracept Reprod Health Care 2008;13(suppl 1): 13-28.
39. Mansour D, Bahamondes L, Critchley H, Darney P, Fraser IS. The management of unacceptable bleeding patterns in etonogestrel-releasing contraceptive implant users. Contraception 2011;83:202-10.
40. Phaliwong P, Taneepanichskul S. The effect of mefenamic acid on controlling irregular uterine bleeding second to Implanon use. J Med Assoc Thai 2004;87(suppl 3):S64-8.
41. Weisberg E, Hickey M, Palmer D, O'Connor V, Salamonsen LA, Findlay JK, et al. A pilot study to assess the effect of three short-term treatments on frequent and/or prolonged bleeding compared to placebo in women using Implanon. Hum Reprod 2006;21:295-302.
42. Weisberg E, Hickey M, Palmer D, O'Connor V, Salamonsen LA, Findlay JK, et al. A randomized controlled trial of treatment options for troublesome uterine bleeding in Implanon users. Hum Reprod 2009;24:1852-61.
43. Dilbaz B, Ozdegirmenci O, Caliskan E, Dilbaz S, Haberal A. Effect of etonogestrel implant on serum lipids, liver function tests and hemoglobin levels. Contraception 2010;81: 510-4.
44. Shokeir T, Amr M, Abdelshaheed M. The efficacy of Implanon for the treatment of chronic pelvic pain associated with pelvic congestion: 1-year randomized controlled pilot study. Arch Gynecol Obstet 2009;280:437-43.
45. Walch K, Unfried G, Huber J, Kurz C, van Trotsenburg M, Pernicka E, et al. Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis-a pilot study. Contraception 2009;79: 29-34.
46. Beerthuizen R, van Beek A, Massai R, Makarainen L, Hout J, Bennink HC. Bone mineral density during long-term use of the progestagen contraceptive implant Implanon compared to a non-hormonal method of contraception. Hum Reprod 2000;15:118-22.
47. Bonny AE, Ziegler J, Harvey R, Debanne SM, Secic M, Cromer BA. Weight gain in obese and nonobese adolescent girls initiating depot medroxyprogesterone, oral contraceptive pills, or no hormonal contraceptive method. Arch Pediatr Adolesc Med 2006;160:40-5.
48. Schelar E, Franzetta K, Manlove J. Repeat teen childbearing: differences across states and by race and ethnicity. Child Trends Research Brief. Washington, DC: Child Trends; 2007. Available at: http://www.childtrends.org/ Files/Child-Trends-2007-10-25-RB-Repeat.pdf. Retrieved June 22, 2012.
49. Chen BA, Reeves MF, Hayes JL, Hohmann HL, Perriera LK, Creinin MD. Postplacental or delayed insertion of the levonorgestrel intrauterine device after vaginal delivery: a randomized controlled trial. Obstet Gynecol 2010;116: 1079-87.
50. Tocce K, Sheeder J, Python J, Teal SB. Long acting reversible contraception in postpartum adolescents: early initiation of etonogestrel implant is superior to IUDs in the outpatient setting. J Pediatr Adolesc Gynecol 2012;25:59-63.
51. Pazol K, Zane SB, Parker WY, Hall LR, Berg C, Cook DA. Abortion surveillance-United States, 2008. Centers for Disease Control and Prevention (CDC). MMWR Surveill Summ 2011;60(SS-15):1-41.
52. Goodman S, Hendlish SK, Reeves MF, Foster-Rosales A. Impact of immediate postabortal insertion of intrauterine contraception on repeat abortion. Contraception 2008;78: 143-8.
53. Ortayli N, Bulut A, Sahin T, Sivin I. Immediate postabortal contraception with the levonorgestrel intrauterine device, Norplant, and traditional methods. Contraception 2001;63:309-14.
54. Kurunmaki H. Contraception with levonorgestrel-releasing subdermal capsules, Norplant, after pregnancy termination. Contraception 1983;27:473-82.